Literature DB >> 8741946

Amphetamine and negative symptoms of schizophrenia.

M Sanfilipo1, A Wolkin, B Angrist, D P van Kammen, E Duncan, S Wieland, T B Cooper, E D Peselow, J Rotrosen.   

Abstract

The purpose of this study was to assess further the effect of amphetamine on negative symptoms of schizophrenia. Thirty-seven schizophrenic males meeting DSM-III criteria were rated with the Brief Psychiatric Rating Scale, the Abrams and Taylor Scale, and the Abnormal Involuntary Movements Scale before and after double-blind administration of either amphetamine (n = 26) or placebo (n = 11). Our results indicated that amphetamine administration generally did not improve negative symptoms, even when accounting for changes in positive symptoms. However, greater baseline negative symptoms were associated with a modest diminution after amphetamine treatment. Therefore, amphetamine may modestly improve negative symptoms in those schizophrenics in whom this symptomatology is more severe.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8741946     DOI: 10.1007/bf02246180

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

Review 1.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia.

Authors:  A A Grace
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

2.  Implications of normal brain development for the pathogenesis of schizophrenia.

Authors:  D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1987-07

3.  Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.

Authors:  B Angrist; J Rotrosen; S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

Review 4.  Dopamine in schizophrenia: a review and reconceptualization.

Authors:  K L Davis; R S Kahn; G Ko; M Davidson
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

5.  Differential response to amphetamine in schizophrenia.

Authors:  Z Cesarec; A K Nyman
Journal:  Acta Psychiatr Scand       Date:  1985-05       Impact factor: 6.392

6.  d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.

Authors:  D P van Kammen; W E Bunney; J P Docherty; S R Marder; M H Ebert; J E Rosenblatt; J N Rayner
Journal:  Am J Psychiatry       Date:  1982-08       Impact factor: 18.112

7.  Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology.

Authors:  A Wolkin; M Sanfilipo; B Angrist; E Duncan; S Wieland; A P Wolf; J D Brodie; T B Cooper; E Laska; J P Rotrosen
Journal:  Biol Psychiatry       Date:  1994-09-01       Impact factor: 13.382

8.  Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.

Authors:  T E Goldberg; L B Bigelow; D R Weinberger; D G Daniel; J E Kleinman
Journal:  Am J Psychiatry       Date:  1991-01       Impact factor: 18.112

9.  Dextro-amphetamine diminishes negative symptoms in schizophrenia.

Authors:  D P van Kammen; J J Boronow
Journal:  Int Clin Psychopharmacol       Date:  1988-04       Impact factor: 1.659

10.  Negative symptoms and hypofrontality in chronic schizophrenia.

Authors:  A Wolkin; M Sanfilipo; A P Wolf; B Angrist; J D Brodie; J Rotrosen
Journal:  Arch Gen Psychiatry       Date:  1992-12
View more
  7 in total

Review 1.  Management of schizophrenia in children and adolescents: focus on pharmacotherapy.

Authors:  Gabriele Masi; Francesca Liboni
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Striatal dopamine receptor plasticity in neurotensin deficient mice.

Authors:  Lucy G Chastain; Hongyan Qu; Chase H Bourke; P Michael Iuvone; Paul R Dobner; Charles B Nemeroff; Becky Kinkead
Journal:  Behav Brain Res       Date:  2014-11-15       Impact factor: 3.332

Review 3.  Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models.

Authors:  Patricio O'Donnell
Journal:  Schizophr Bull       Date:  2011-05       Impact factor: 9.306

Review 4.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

Review 5.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Authors:  Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

6.  SSR504734 enhances basal expression of prepulse inhibition but exacerbates the disruption of prepulse inhibition by apomorphine.

Authors:  Philipp Singer; Weining Zhang; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2013-06-05       Impact factor: 4.530

7.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.